COLUMN

5 Billion Yen Blockbuster?

June 20, 2018
Shinya Sato What has been billed as a potential multibillion-dollar blockbuster has now hit the Japanese hemophilia market. Despite much hype worldwide, though, the hemophilia A therapy Hemlibra (emicizumab) carries a peak sales forecast of just five billion yen in…

To read the full story

COLUMN

By Reiji Anasako

Kyowa Hakko Kirin’s first and only Rituxan (rituximab) biosimilar in Japan is showing a faster-than-expected uptake in the market, with the company racking up 4.3 billion yen from the cancer drug in 2018, far beyond its initial 3.2 billion yen…

Members of a key reimbursement policy panel appear to be becoming more and more open to the industry’s call for…

By Philip Carrigan

With a cursory glance, recruitment is easily defined. We’re here to help place candidates into the vacancies our clients need to fill. Armed with a pen and paper, you could even map out the process.• We study the market• We…

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…